Sanofi, in its third-quarter financials posted early Thursday morning, outlined a list of delays for a number of key assets as it dropped a biotech-partnered drug.nFirst up, those delays: We already knew its hemophilia hopeful fitusiran had problems after Sanofi started a new lower dose cohort in its phase 3 amid safety concerns, but now we know filing for the RNAi drug is not expected until 2024, after originally being penned in for next year.
French pharma company Sanofi has announced that it has halted the clinical programme of venglustat in autosomal dominant polycystic kidney disease (ADPKD).
Market Place
Share